Embed Size (px)
Citation preview
An Emerging Bio-SectorStem Cells
FRONT COVER INSIDE(BLANK)
An Emerging Bio-SectorAn Emerging Bio-SectorStem Cells Stem Cells
Life Sciences Knowledge Banking Team, YES BANK
March, 2012
No part of this publication may be reproduced in any form by photo, photoprint,
microfilm or any other means without the written permission of YES BANK Ltd.
YES BANK Ltd
Registered and Head Office
9th Floor, Nehru Centre
Dr. Annie Besant Road,
Worli, Mumbai - 400 018, INDIA
Tel : 91 22 66699000
Fax : 91 22 24900314
Northern Regional Office
48, Nyaya Marg, Chanakyapuri
New Delhi - 110021
Tel : 91 11 46029034
Fax : 91 11 2625 4000
Email : [email protected]
Federation of Asian
Biotech Associations [FABA]
401, Laxmi Nivas, Greenlands Circle,
Ameerpet, Hyderabad - 500 016,
Andhra Pradesh, India
Tel: +91 (40) 2341 - 5667/5668
Fax: +91 (40) 2341 - 5669
E-mail: [email protected]
Stem Cells : An Emerging Bio-Sector
The information and opinions contained in this document have been compiled or arrived
at from sources believed to be reliable, but no representation or warranty expressed is
made to their accuracy, completeness or correctness. This document is for information
purpose only. The information contained in this document is published for the assistance
of the recipient but is not to be relied upon as authoritative or taken in substitution for the
exercise of judgment by any recipient. This document is not intended to be a substitute for
professional, technical or legal advice. All opinions expressed in this document are
subject to change without notice.
Neither YES BANK Ltd. nor FABA or any other legal entities in the group to which it
belongs, accept any liability whatsoever for any direct or consequential loss howsoever
arising from any use of this document or its contents or otherwise arising in connection
herewith.
CONTACT ADDRESS
DISCLAIMER
TITLE
YEAR
COPYRIGHT
AUTHORS
FOREWORDFo
rew
ord
..India today is one of the fastest growing economies in the world
and is expected to account for 10% of the growth in global GDP
from 2010 to 2020. As a growing consumer market, a low cost
manufacturing location and a source of skilled manpower, no
global company can afford to overlook India and exclude it from their growth aspirations.
The financial crisis which has severely impacted the growth of the developed economies
over the last few years has had a significantly lesser impact on India's growth and investors
continue to be drawn towards India.
India is emerging as a Key player in the global business arena in several sunrise sectors,
including the Life Science industry and its various segments. The country has already
made significant improvements in its basic health indicators since Independence and
various Government departments, agencies and the industry segments are working
together to reach the healthcare standards of the developed countries at an affordable
cost. India has a crucial role to play in the development of the global Life Sciences industry
and is in position to take a lead in the emerging sub-sectors.
Developing countries such as India and China are emerging as leading Biotechnology
markets in Asia. Indian Biotech market has in fact tripled over the last five years, and is
projected to grow at a CAGR of over 20% to achieve a market size of USD 8 billion by
2015. The Stem Cell segment is an emerging sub-segment of the Biotechnology industry.
This nascent and highly knowledge-intensive sector has reached an inflection point and a
strong and supportive regulatory environment and policy are now essential to drive
further growth and private investments to help the stem cell to achieve its full market
potential in India.
YES BANK and Federation of Asian Biotech Associations [FABA] are deeply committed
towards supporting the growth of the Biotech industry and its sub-sectors in India, and we
proactively participate at various levels to create innovative business models and provide
advisory support to this core industry. We also Endeavour to share our analysis and
expertise to address specific industry issues related to this sector.
We are confident that this Knowledge Report will be able to add to your understanding of
the upcoming stem cell industry.
Sincerely,
Dr. B. S. Bajaj Dr. Rana Kapoor
Secretary General Founder, Managing Director & CEO
Federation of Asian Biotech Associations YES BANK Ltd.
Co
nte
nts
..CONTENTS •
•
•
•
•
•
•
•
Introduction : Stem Cell Segment 05
Business & Market Potential 06
Key Players 07
Key firms in India 07
International 08
Govt. Initiatives and the Regulatory Environment in India 10
Opportunities 11
Challenges 12
YES BANK's Life Science Segments 14
YES BANK deals in the Life Science Sector 15
•
•
Introduction: Stem Cell Segment
Stem cells is an emerging field which has the potential of altering the world of diagnosis, treatment
and drug discovery. “Stem Cells are cells with the ability to divide for indefinite periods in culture
and to give rise to specialized cells.” Stem cells are different from other cell types in two important
characteristics - they are unspecialized cells capable of renewing themselves through cell division,
sometimes after long periods of inactivity; and under certain physiologic or experimental
conditions, they can be induced to become tissue- or organ-specific cells with special functions.
The sources of Stem Cells are embryos and adult tissues.
Stem cell treatment serves as an internal repair system, dividing to replenish other cells In some
organs, such as the gut and bone marrow, stem cells regularly divide to repair and replace worn out
or damaged tissues. In other organs, however, such as the pancreas and the heart, stem cells only
divide under special conditions. These characteristics of Stem Cells are driving Scientists to be able
to tackle conditions like Alzheimer's disease or Parkinson's disease, which currently are incurable.
It is believed that once stem cell technology is fully developed, patients could be able to grow back
a failing kidney, burnt skin or even a malfunctioning lung.
Stem Cells industry is growing rapidly due to increasing focus on commercialization of private and
public research, formulation of regulatory frameworks and public interest. This growth though is
tempered with religious restrictions on the sources of the Stem Cells. Stem Cell treatments have shown promise in the following segments:
• Oncology
• Cardiology
• Bone & cartilage
• Neurology
• Hematology
• Metabolic (Diabetes)
Among these therapeutic areas, neurology is forecasted to have the strongest growth rate, with a
CAGR of nearly 25% by 2015. Hematology and diabetes are also projected to lead the stem cell
market in the coming years.
The industry consists of new startups that are converting promising research into new products and
services, hospitals that are creating Stem Cell based treatments for captive customers and a number
of major pharmaceutical and biotech players who are also branching into this segment, especially
in the area of regenerative medicine, to capture the growth opportunity. While this is leading to an
increased competition for the pure players, it is also leading to increased awareness of the benefits
o stem cells.
The Stem Cell market could be segmented as follows:
• Stem Cell Products: Adult stem cell, human embryonic stem cell, and other stem cell types.
• Stem Cell Services: Stem cell banking, stem cell acquisition and testing, drug discovery and
target identification, isolation/characterization services, and molecular biology.
• Stem Cell Technologies: Stem cell acquisition, stem cell production, cryopreservation, and
expansion and subculture.
• Stem Cell Applications: Regenerative medicine – neurological disorders, orthopedics, cancer,
05
hematological disorders, myocardial infarction and cardiovascular diseases, injuries, diabetes,
liver disorder, incontinence, and drug development.
At present, adult stem cell therapy dominates this segment, with almost 60% of total market share,
due to its comparative uncontroversial nature. Further, in India most private players are primarily
focusing in the area of stem cell banking, with a few notable exceptions.
The benefits of stem cell therapy are attracting an increasing number of practitioners and
organizations to invest, create and commercialize promising technologies. Intensive R&D efforts
and the increasing investments into research on stem cells therapy is expected to improve the
efficacy of stem cell treatment and thus further drive growth in the coming years. However, the
prevailing high cost of these therapies may slow down the market growth.
According to Axis Research Mind, a reputed market forecast organization, the global stem cell
therapy market was pegged at USD 21 Billion in 2010 and is expected to cross USD 60 Billion by
2015, tripling in size. Further, the global cord blood stem cells banking market for 2010 is
estimated at about USD 4.0 Billion and is projected to reach USD 15.0 Billion by 2015.
• Although North America, which currently constitutes around 60% of the global stem cell
market, will continue to lead in this segment by value, the Asian economies are projected to
grow at a much higher CAGR of over 25% in the 2010-2015. This higher growth rate is due to
the improved investment scenario in these regions and the stronger economic growth.
• Europe is likely to maintain its strong position in this segment and will continue to remain
competitive with the emerging economies due to the improving health consciousness in the
area. However, European market for stem cells is being partially held back by issues such as
opposition to embryonic stem cell research in Germany, Poland, and Italy.
• Asia emerged as the major market in the rest of world market, with countries such as Japan,
China, Singapore, Korea, and Australia emerging as the major hubs for stem cells research.
• India has the potential to become a leader in the stem cell segment, with its growth projected to
outstrip that of most developed and emerging markets in this area. India's positive regulatory
environment is a major contributing factor in this. The Indian stem cell therapy market is
projected to grow at an annual growth rate of around 15%, driven by robust investment from
the government and private players.
YES BANK believes that the sector could outperform the above projections with government
support; sustenance of private companies through technology transfers; and most importantly
financing institutions. The real potential of the stem cell sector will be realized once the
pipeline of products is commercialized and the therapeutic benefits are proven.
In India, there are very few players in the stem cell sector and these are all in very nascent stages.
Industry consolidation with global players entering into the market through mergers and acquisition
route could propel industry growth.
Business & Market Potential
06
Key Players
Key Firms in India
Although the stem cell industry is still in its nascent stages, there are some outstanding pure-play
companies in this area, in India and globally, whose progress bodes very well for the future of this
developing sector.
There are 3 primary sub-sectors are :
• Stem cell Banking
• Stem cell Research
• Stem cell product development and its commercialization
At present, most players in India are concentrated in the business areas of stem cell banking and
research, with a few moving into the stage of product development and its commercialization.
In India at present there are 4 main private players in the various sub-sectors of the stem cell
segment. These are Reliance Life Sciences, LifeCell, Cryobanks India and Stempeutics.
07
Besides these companies, there are also some key players in India which are incubated out of
Government Institutes, Healthcare Facilities and even start-ups. Some examples are as follows:
• Stemade Biotech: Starting its operations in late 2010, Stemade had established its presence in
six metros and is a pioneer in the area of dental stem cell banking. The company plans to expand
operations to 6 new Indian cities by end of 2012 and also to international markets of Middle East
and Singapore. The company entered into a tie-up with Cholamandalam Distribution Services
(CDSL) to provide its customers with 'bio-insurance'. Through this tie-up, Stemade Biotech will
provide training, technical, logistics and product-related services to Cholamandalam and its
customers.
• inStem: The Institute for Stem Cell Biology and Regenerative Medicine (inStem), is an
autonomous institute of the Department of Biotechnology, located at NCBS, Bangalore. The
institute is conducting interdisciplinary basic and translational research in the areas of stem cell
and regeneration biology. For this purpose, in March 2011, the institute signed a Memorandum
of Understanding with the US-based California Institute for Regenerative Medicine (CIRM) to
jointly fund collaborative research projects that bring together top stem cell scientists in India
and California.
• Nichi-In Center for Regenerative Medicine (NCRM): An Indo-Japan (JV) joint venture institute
carrying out research, training and clinical applications-protocol development in regenerative
medicine, with an emphasis on stem cells, progenitor cells and autologous adult cells with
regenerative capability to take them to clinical application. NCRM is the first institute in India to
start providing autologous NK cell based immuno-cell therapy (AIET) for cancer and has been
providing stem cell isolation, enrichment and expansion services to partner hospitals all over
India to treat various diseases as per Indian Council of Medical Research (ICMR) guidelines.
• Tran-Scell Biologics: Founded in 2009, the company is investing INR 380 crore to set up a stem
cell research-cum-therapeutic facility in Hyderabad to develop therapeutic applications.
• EmProCell Clinical Research: The company formed in 2006 as a JV between Mumbai-based
Lok-Beta Pharmaceuticals and Denmark-based Citti Pharm, and focuses on development of
Stem Cell therapy. The company's research is primarily focused on cell transplantation and
tissue therapy using embryonal pluripotential progenitor cells.
There are emerging global stem cell companies that are indicative of the success of Indian Stem Cell
Industry. These international players have been very successful in forming development and
marketing alliances, in commercializing and out-licensing their technology and raising funds
through angel, venture funds and public markets. Key examples are:
• Osiris: A US-based stem cell company focused on developing and marketing products to treat
medical conditions in the inflammatory, autoimmune, orthopedic and cardiovascular areas,
from a readily available and non-controversial source – adult bone marrow. Phase III trial for a
product, Prochymal, initiated in 2006 and has recently received approval for expanded
application from US FDA. The company's lead investor is the Swiss VC fund Friedli Corporate
Finance. In 2008, Osiris formed a USD 1.2 billion research and marketing alliance with
Genzyme. Also in 2008, the company sold its first product to win market approval, Osteocel-
regenerates bone, to Nuvasive for around USD 85 million.
• Gamida Cell: The Israel-based company's pipeline consists of products derived from umbilical
International
08
09
cord blood for treating a wide range of conditions including blood cancers, solid tumors,
autoimmune and metabolic diseases. The company's lead product, StemEx is in Phase III as a
treatment for bone marrow transplant for blood cancer patients, and is to be launched in 2013.
Gamida Cell's current shareholders include Elbit Imaging, Clal Biotechnology Industries,
Israel Healthcare Venture, Teva Pharmaceutical Industries, Amgen, Denali Ventures and
Auriga Ventures.
• Mesoblast: The Australia-based company's target cardiovascular conditions, diabetes,
inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone
fractures, cartilage degeneration and musculoskeletal conditions. Several of its products are
ready for Phase III trials. The company listed on the Australian Securities Exchange in December
2004. Mesoblast and Teva established a strategic alliance to commercialize adult stem cell
products for degenerative conditions of the cardiovascular and central nervous systems. The
company also has strategic alliances with Lonza and Cephalon.
• Athersys Inc.: The US-based company is focusing on its primary programme MultiStem, which
it is evaluating for treating multiple disease conditions ranging from inflammatory and immune
to cardiovascular to neurological. Currently the trials are mainly in Phase I and II stage, with
Phase III trials projected to start in 2013. The company has development and
commercialization collaborations with Bristol-Myers Squibb, Angiotech Pharmaceuticals and
Pfizer. The company was funded by firms like Radius Ventures, OrbiMed Advisors, MPM
BioEquities, etc. and succeeded in going public and raising USD 65 million via a reverse merger
in 2007.
Several companies are also focused on niche technology for conducting stem cell research. These
include:
• Life Technologies Inc.: The US-based company leader in stem cell research technology offers a
complete portfolio of stem cell products and services, like Giboc- stem cell culture products,
Invitrogen- stem cell differentiation and engineering, including a wide array of stem cell
analysis tools.
• BD Biosciences: BD Biosciences has over 20 years of leadership in the cell separation space.
With its presence from isolation to analysis and its wide variety of advanced functional enzymes
and cell culture technology, BD has contributed immensely in the Stem cell innovation. BD TM TM Biosciences – Discovery labware and its BD Falcon , BD BioCoat and other such products
have helped researchers in investigating mechanisms that dictate stem cell growth and
differentiation. BD Biosciences was the first to commercialize systems and reagents for
characterizing and isolating hematopoietic stem cells for research use.
• Sigma-Aldrich : Sigma has contributed significantly in Stem Cell research , it has enabled
scientists to research curative discoveries in numerous areas from cancer to diabetes to
neurogenerative diseases. Sigma® Lifesciences has a portfolio of gene editing and gene
silencing technologies including CompoZr® ZFN technology and MISSION® RNA Libraries.
• Lonza : The Swiss company has also been able to develop and provide products for Stem Cell TMresearch. Lonza's Clonetics Primary Normal Cell and Media has over 50 authenticated
primary human and animal cell types with optimized media for growth and maintenance.
Clonetics™ Primary Diseased Cells has Primary cells derived from patients with COPD, asthma,
Type 1 and Type 2 diabetes. Apart from this Lonza also provides contract manufacturing for
stem cell therapy products. In this regards Lonza established a first of its kind commercial-scale
allogeneic good manufacturing practice (GMP) manufacturing facility along with an additional
capacity to manufacture GMP grade cell culture media.
Stem cells are seen as the future of medicine and at present no country or market has a clear lead in
this area. The US could have had the lead in the stem cell segment, but for the delay in research on
ethical and political grounds. However, in 2010, the Obama administration announced an increase
in government funding for stem cell research, which could lead to several key developments in the
near future. India offers a commercially and legally attractive environment for adult stem cell
entrepreneurs, in contrast with the regulatory setbacks faced by the segment in other markets,
including the US.
There are at present no laws governing stem cell research, however specific guidelines have been
laid out to classify stem cell use into three categories: permissive, restricted and prohibited.
In 2011, the Union Health Ministry constituted the Indian National Apex Committee for Stem Cell
Research and Therapy (NAC-SCRT), which will be reviewing and monitoring the stem cell research
in the country. In 2007, the Union health ministry had formulated the Guidelines for stem cell
research regulation in 2007, prescribing strict procedures for sourcing and use of stem cells by
research institutions. The NAC-SCRT currently revising this guidelines. The ICMR has also set out
the following guidelines for the segment to proactively stop the misuse of this potential technology:
• Stem cell therapy is classified as experimental, but adult stem therapy is permissible. Further,
ICMR allows the use of embryonic stem cells if the condition or disorder is considered
incurable.
• The Stem cell therapy provider must have an Institutional Ethics Committee and a Monitoring
committee in other words an Institutional Committee for Stem Cell Research and Therapy and
(ICSCRT). All trials on stem cells have to be passed through them and after the establishment of
safety and efficacy, they can be offered to the patients.
• Stem cell provider must have a Class 10,000 cGMP facility for handling the product.
• The guidelines also set forth requirements for the registration and monitoring of clinical trials by
multiple government bodies. But these have yet to be passed into law.
India is one of the most liberal and proactive countries in the space, with the Department of
Biotechnology having allocated over USD 60 million* to stem cell research in the 2005-2010
period.
The Indian government's effort is primarily aimed at understanding the fundamentals of the
functioning of stem cells and conducting clinical trials to gauge their effectiveness in treatments.
The leading organization in this program is the National Centre for Biological Sciences (NCBS) in
Bangalore. Other key government backed institutes focusing on applied research in the area are:
· Centre for Cellular and Molecular Biology at Hyderabad: Set up in 2011 with an investment of
INR 24 crore, CCMB set up a unique Clinical Research Facility for Stem Cell Technologies and
Regenerative Medicine. The Department of Science and Technology (DST) and CSIR funded
the construction of the new building.
· Center for Stem Cell Research at CMC Vellore: The centre was set up at a cost of about INR 20
Govt. Initiatives and the Regulatory Environment in India
10
crore in collaboration with the Department of Biotechnology processes stem cells according to
standards does clinical studies. The centre has a broad mandate for developing translational
(applications oriented) research, focusing on the use of stem cells derived from bone marrow
and umbilical cord blood.
· National Centre for Cell Sciences (NCCS) at Pune University: The centre was established with
a mandate of basic research, teaching & training, and as a national repository for cell lines was
established with DBT backing.
· National Brain Research Centre near Delhi: NBRC scientists have been successfully
maintaining and differentiating human embryonic stem cells into neurons for repairing brain
injury. In addition, cures for Alzheimer's disease are being tested in animal models using plant
extracts from traditional medicine.
· LV Prasad Eye Institute: The institute inaugurated its Stem Cell Laboratory in 2004, with a grant
from DBT. The Cornea and Anterior Segment unit at LVPEI have treated over 700 patients using
limbal stem cell transplantation and around 20 patients have also undergone corneal
transplants, with a high rate of success. The institute is further developing its research on
treatments which use isolation, characterization and differentiation of both CPE (Ciliary-
pigmented epithelium) and LSC (Limbal stem cells) towards retinal progenitor lineage for their
possible use in cell replacement therapy.
Several key markets have limited the use of stem cells through various regulations due to their
nascent success history and the negative publicity associated with some treatments.
China: In 2009, China took concrete steps to limit the marketing and use of stem-cell-based
treatments for medical conditions in which their effectiveness remains unproven. However, the
penalities, fines and the process for decision-making in this regard remains unclear. Further, the
close ties between China's many stem cell purveyors, its municipal and military hospitals, and
universities makes the effective implementation of these steps difficult.
USA: The United States has its own body of rules for the testing and clinical application of stem
cells, which rest on the fundamental definitions set forth in Part 1271 of Title 21 'Food and Drugs' of
the Code of Federal Regulations, which deals generally with human cells, tissues and cell- and
tissue-based products. Any cells that are from a source other than the patient receiving them, that
are more than minimally manipulated, or that act throughout the body or through metabolic activity
fall under US FDA requirements for clinical trials and marketing.
While the requirements for scientific testing and caution prior to the introduction of novel cell-
based treatments into medical use that are in place in the United States and Europe may not be
perfect, there does not appear to be a better alternative for protecting patients from exploitation and
possible harm. Several factors are impeding the regulation of the stem cell industry globally. These
include competing financial interests; sluggish or entrenched legal systems; activism on the part of
companies and advocates; overburdened regulators; uncertainties over the legal status of cell
therapies; and a sense of unwillingness to restrict the autonomy of patients urgently seeking care.
Opportunities abound in this area and financial community is actively looking into this field for
investments. As commercialization activities gather speed, the following are some of the where
focus and investments could transform the indutry
Opportunities
11
12
· Boost to Stem Cell Research: Technological advancements, rising number of research groups
engaged in stem cell research, and substantial investments from governments in leading global
markets are the key factors driving growth in stem cells research worldwide. Further, the market
is also driven by rising incidence of life-threatening diseases, large unmet needs and rising costs
of traditional drug development.
· Lowering Healthcare Costs: Advancement in stem cell research can help decrease the
increasing healthcare cost associated which are being tackled by almost every developed
market. Since stem cells target the cause of a disease, they have the ability to potentially
eradicate the disease and thus save recurring costs which can go on for years.
· Impact on Medical Tourism: A strong stem cell sector in India will also have a beneficial impact
on the growing medical tourism industry in the country. At present, stem cell treatment is
severely restricted in all major markets, with India being one of the few exceptions. It's
necessary for us to focus on developing this sector and gain a competitive advantage from it for
the rest of the Life Sciences industry.
· Large Un-tapped Domestic Opportunity: It is estimated that stem cell banking customers in
India will quadruple in the 2 year period of 2010 to 2012. But this is still far behind the number
of customers in Europe and USA, which is nearly 100,000 every year. This indicates a large
untapped opportunity which is yet to be tapped in the domestic market.
· Government Support: The Indian Government's proactive support for this sector have resulted
in sufficient availability of skilled manpower and the required infrastructure, which can attract
foreign institutes and private companies for collaborative research with Indian institutes and
organizations, thus further accelerating the development of this sector.
The challenges associated with the sector are those of a developing industry segment in its initial
stages, where the regulatory framework is as yet not formed and the awareness levels regarding the
products and its benefits are still to be propagated.
· Lack of Legislation: The legislation for this sector still is at the draft stage. A regulatory
framework governing the sector, instead of the guidelines existing at present is essential for the
proper growth of stem cell research and applications in India. There are also no guidelines
regarding pricing, which results in certain unproven injections being sold for around INR
80,000.
· Quality and Ethical Issues: Several companies are taking advantage of the lack of laws
governing the stem cell segment and advertise their therapies and clinical trials as ICMR
approved. However, given the multi-tiered system of registration and approvals recommended
in the ICMR's guidelines, some of these are based on fraudulent or exaggerated claims. Further,
there are also ethical worries on the side-effect of such treatment.
· Lack of Awareness: The general public is not aware of stem cell banking and its uses. A
concentrated marketing and awareness campaign are necessary for these treatments to gain
acceptance. There have already been several initiatives in this area, with movie stars promoting
banking of stem cells.
· Nascent success history: Till date clinical trials for no stem cell treatment has completed the
entire course and as such these treatments are still in the unproven stage. There is criticism of
these products from several quarters, especially doctors from the developed markets, who
believe that stem cell treatment could be dangerous and at best, ineffective.
Challenges
Although the Government of India has provided extensive support to this segment, it still needs to
do much more to help push India to a leadership position in this area. Special provisions like 10-
year tax benefits, duty exemptions, fast tracking the approval process by giving it a status of orphan
drug (as done in the US), etc. are some measure which could be very helpful.
In Conclusion
Stem Cell industry is a high-growth but nascent one, which has the ability to transform the field of
diagnostics and therapeutics. With proactive governmental support and policies, private and public
investments and public advocacy, this industry is poised to grow by leaps and bounds.
13
14
Knowledge Reports
India Pharmaceutical Industry: 2008
eHealth- Opportunities & Challenges in India: 2006
Indian Pharmaceuticals Industry: 2007
Biotechnology- MacroScope of the Microscope: 2005
Financing Ecosystem of Indian Life Science Industry: 2011
Indian Biotechnology Industry: 2006
Health and Healthcare in India: 2006
Healthcare Services in India: 2009
India Life Sciences: Vision: 2010
Pharmaceuticals (Formulations
& API)
Healthcare
Biotechnology (including
agri-biotech)
Alternative Medicine
(Ayurveda,Homeopathy
etc)
Nutrition and natural
products
Medical equipment and devices
Specialty chemicals
Contract research &
Manufacturing services
LifeScience Sectors
YES BANK's Life Science Segments
7 Years of Thought Leadership
15
YES BANK deals in the Life Science Sector
Sumit GuptaSenior PresidentEmerging Corporates Banking, YES BANKTel: +91 11 4602 9004Email: [email protected]
Vishal GandhiSenior Vice President & HeadLife Sciences Knowledge Banking, YES BANKTel: +91 11 4602 9063 / +91 98107 02334Email: [email protected]
About YES BANK
YES BANK, India's 4th largest private sector Bank, is the outcome of the professional & entrepreneurial
commitment of its Founder, Dr. Rana Kapoor and his top management team, to establish a high quality,
customer centric, service driven, private Indian Bank catering to the Future Businesses of India. YES BANK has
adopted international best practices, the highest standards of service quality and operational excellence, and
offers comprehensive banking and financial solutions to all its valued customers.
YES BANK has a knowledge driven approach to banking, and a superior customer experience for its Branch
Banking (Individuals and SMEs) and Corporate clients. As a part of this knowledge driven approach, YES
BANK focuses on key growth sectors like Infrastructure, Lifesciences, Food & Agribusiness,
Telecommunications, Information Technology, Renewable Energy, Media & Entertainment, Manufacturing
and Textiles, among others.
YES BANK's differentiated approach to banking provides industry specific financial solutions which facilitate
superior structuring and tailored financial solutions. YES BANK is steadily evolving as the Professionals Bank
of India with the long term mission of “Building the Best Quality Bank of the World in India”
About FABA
The Federation of Asian Biotech Associations [FABA], is a non-profit registered society engaged in various
activities related to promoting Biotechnology in Asian countries. FABA, with its humble beginning in 2004,
has achieved a significant landmark in creating a common platform for interaction among member countries
and discuss the issues of common interest for improving the Biotechnology space including technology
transfer, resource sharing, business collaborations, industry-academia linkage, cross border trade and
investments, etc. among its member countries.
Headquartered at Hyderabad, FABA has a strong network base in 20 Asian countries including China, India,
Bangladesh, Malaysia, Philippines, Russia, Kazakhstan, Israel, Iran, Pakistan, Indonesia, Nepal, Japan, South
Korea, Singapore, Thailand, Sri Lanka, and UAE.
FABA has been organizing various events focusing on Biotechnology and related topics. One such mega
event is BioAsia: The Global Biobusiness Forum which is been organized by FABA on behalf of government
of Andhra Pradesh in association with Pharmaceutical Export Promotion Council (Pharmexcil), Govt. of India
in Hyderabad since 2006 every year. BioAsia over the years has emerged as a Global Brand and has been
offering the most sought platform for convergence of the business leaders, policy makers, investors, etc.
BACK COVER INSIDE (BLANK)
